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A B S T R A C T
Objectives: To study the role of metabolic modulator (trimetazidine: TMZ) in dilated cardiomyopathy
(DCM). Optimizing altered substrate metabolism in heart failure (HF) with metabolic modulators allows
more efﬁcacious energy production from glucose than from free fatty acids.
Methods: 100 patients of DCM (47.7 years, NYHA class 2.17, LVEF 27.3%) were randomized to TMZ
(20 mg tid, n = 50) vs conventional therapy (n = 50). Functional status, BNP and various echocardio-
graphic parameters were assessed at 3–6 months.
Results: At 3 months, TMZ group had signiﬁcantly improved NYHA class (2.25 vs 1.85), 6 min walk test
(349.7 vs 402 m), LVD-36 score (25.5 vs 21) and BNP (744.7 vs 248.3 pg/ml), all p 0.001. Signiﬁcant
improvement was also seen in LV end-systolic (LVESV, 87.1  27.5 vs 78.5  24.9 ml/m2, p 0.001), LV end-
diastolic volumes (LVEDV, 117.6  29.3 vs 110.9  27.4 ml/m2, p 0.001), LVEF (27 vs 30.9%, p 0.001) and LV
wall stress (90.2  18.9 vs 71.1  13.2 dyn/cm2, p 0.0001). The % change in LVESV, LVEDV, LVEF and LV wall
stress was 9.5%, 5.4%, +8.4% and 21.8%. Other echo parameters also improved after 3 months of TMZ (E/A
ratio 1.9 vs 1.2, p = 0.001, E/A VTI 2.7 vs 1.6, p = 0.001, myocardial performance index, MPI 0.8 vs 0.7,
p = 0.0001), Tissue Doppler parameters (E/E0 septal (19.7 vs 12.5, p = 0.001) and E/E0 lateral (13.3 vs 9.4,
p = 0.0001)). Patients in control group had no change in NYHA class, LVD-36 scores, LV volumes or LVEF at
3 months although BNP and LV wall stress reduced to a slight extent. Patients on TMZ had further
improvement in NYHA class, walk test, BNP levels and echocardiographic parameters at 6 months.
Conclusions: Metabolic modulators (TMZ) may help in improving LV function in DCM. In this study,
beneﬁt was noted by 3 months with further improvement at 6 months.
 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Chronic heart failure (HF) is a common cause of mortality and
morbidity with increasing prevalence both in the developing and
the developed world.1 Despite advances in pharmacological and
interventional management of these patients, persistent heart
failure with progression of contractile dysfunction and continuing
left ventricular (LV) remodeling is common. The growing numbersAbbreviations: TMZ, trimetazidine; DCM, dilated cardiomyopathy; HF, heart
failure; LV, left ventricular; FFA, free fatty acid; EF, ejection fraction; LVEDD, left
ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimen-
sion; LVEDV, left ventricular end-diastolic volume; LVESD, left ventricular end-
systolic volume; FS, fractional shortening; SV, stroke volume; LVESS, LV wall end-
systolic stress; ACEI, angiotensin-converting enzyme inhibitors; BB, beta-blockers.
* Corresponding author. Tel.: +91 522 2494220; fax: +91 0522 2668073.
E-mail address: akapoor65@gmail.com (A. Kapoor).
http://dx.doi.org/10.1016/j.ihj.2016.04.023
0019-4832/ 2016 Cardiological Society of India. Published by Elsevier B.V. This is an
licenses/by-nc-nd/4.0/).of such patients with attendant high morbidity and mortality and
consequent economic impact on the healthcare systems empha-
sizes the need to evaluate other therapeutic strategies.
Myocardial dysfunction in HF is due to altered substrate energy
metabolism with reduction in mitochondrial oxidative metabo-
lism and down-regulation of glucose and free fatty acid oxidation
(FFA).2 Under resting aerobic conditions, the normal human
myocardium derives most of its energy (60–90%) from oxidation
of FFA’s, while the contribution from carbohydrate metabolism is
only about 10–30%.3,4 Although FFA oxidation yields more ATP
than glycolysis, it is less energy efﬁcient because it consumes more
oxygen. Apart from this, FFA oxidation also inhibits glucose
oxidation through inhibition of pyruvate dehydrogenase leading to
lactate and hydrogen ion accumulation within the myocardium
with intracellular acidosis and inhibition of contractile function.5,6
Studies have demonstrated that the failing heart is associated with
reduced rates of FFA and increased rates of glucose utilization with open access article under the CC BY-NC-ND license (http://creativecommons.org/
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metabolic remodeling probably represents an adaptive cardio-
protective mechanism that can help improve contractile function,
thus slowing the progression of HF and improving prognosis.
Hence metabolic modulators which have the potential to shift
myocardial substrate utilization from FFA toward glucose metab-
olism may have a place in the management of HF patients.
Trimetazidine (1-[2,3,4-trimethoxybenzyl-piperazine dihy-
drochloride], TMZ) is one such metabolic modulator that can
improve myocardial substrate utilization with a shift of energy
production from FFAs to the more energy efﬁcient pathway of
glucose oxidation, by selectively inhibiting mitochondrial long
chain 3-ketoacyl co-enzyme A thiolase, a key enzyme in the B-
oxidation pathway.9 It is known to have anti-ischemic properties
without affecting myocardial oxygen consumption or blood ﬂow or
exerting any negative inotropic and vasodilator effects.10,11 By
maintaining the intracellular levels of phosphocreatine (PCr) and
ATP, TMZ also ameliorates the low PCr/ATP ratio in chronic HF and
hence enhances the recovery of mitochondrial oxidative phos-
phorylation and phosphocreatine resynthesis.12,13 Reduction in
intracellular acidosis, calcium overload, cell apoptosis, ischemia
induced free-radical injury and improvement in endothelial
function further contribute to the proposed beneﬁcial effects of
TMZ in improving myocardial contractile function.14–16
The role of TMZ in patients with HF secondary to ischemic
cardiomyopathy has been established in previous studies which
have demonstrated beneﬁcial effects on symptom status, exercise
duration and LV systolic function.17–21 However only a few studies
with limited patient numbers have assessed its role in patients
with HF secondary to dilated cardiomyopathy (DCM).22–24
We prospectively assessed if addition of TMZ to conventional
treatment in patients with heart failure (HF) secondary to DCM
would improve functional class, exercise tolerance, LV systolic
function and other echocardiographic parameters.
2. Methods
A total of 100 patients with HF and DCM in NYHA in functional
class II–IV and with ejection fraction (EF) 45% (by transthoracic
echocardiography) were included in the study. The study
conformed to the institutional ethical guidelines and patients
were included after obtaining informed consent. All patients had
persistent symptoms despite conventional medical therapy for at
least 3 months prior to the study. Conventional therapy was
deﬁned as optimized up-titration of angiotensin-converting
enzyme inhibitors (ACEI) and beta-blockers (BB) with stable doses
for the last 4 weeks in all cases, and wherever indicated, long-
acting nitrates, digoxin, diuretics, and antiplatelet drugs, as
required. Patients were randomized in a 1:1 fashion to receive
either TMZ (20 mg three times daily in addition to conventional
therapy or conventional therapy alone).
Patients were excluded in case of an acute myocardial infarction
or unstable angina pectoris within previous 3 months, previous
known coronary artery disease, primary valvular disease, history of
any alcohol abuse within 6 months, high-grade arrhythmias,
signiﬁcant renal insufﬁciency (serum creatinine  2.2 mg/dl),
known active neoplastic process, orthopedic or neurological illness
that could limit their ability to exercise.
All patients underwent baseline investigations, including com-
plete hemogram, renal and liver function test, blood sugar, serum
electrolytes, lipid proﬁle and BNP estimation. Levels of BNP were
assessed using ﬂuorescence immunoassay with a commercially
available kit (Alere Triage Cardio 3 Panel, Alere, Inc., San Diego, CA,
USA). Functional exercise capacity was estimated using the 6 min
walk test. The LV dysfunction questionnaire (LVD-36) was used to
measure the impact of LV dysfunction on daily life and well-being.25Echocardiography: All patients underwent detailed echocardiog-
raphy using a GE Vivid 7 ECHO machine (GE Healthcare, Waukesha,
WI). Various 2D Echocardiographic and Doppler indices, including
left ventricular end-diastolic dimensions and volumes (LVEDD,
LVEDV), left ventricular end-systolic dimensions and volumes
(LVESD, LVESV), LV ejection fraction (LVEF), stroke volume (SV)
and fractional shortening (FS) were recorded. The LV dimensions
were obtained from the parasternal long-axis view while LV
volumes were obtained from the apical four- and two-chamber
views’, using the modiﬁed Simpson’s rule, from which ejection
fraction was automatically calculated as the difference between
end-diastolic volume and end-systolic volume normalized to end-
diastolic volume. The LV wall stress (LVESS) was calculated as
LVWS = [BP  (LVESD/2)]/{2  [(systolic IVS + systolic PW)/2]},
where LVESD is LV end-systolic dimension and IVS is interventricu-
lar septum, while Left ventricular (LV) mass (LVM) was calculated by
the Devereux formula.24,26,27
Transmitral ﬂow velocities (peak early: E wave and late: A
wave), their ratio (E/A); velocity time integral (EVTI and A VTI), E
deceleration time were also recorded in all patients. The Tei index,
an echocardiographic/Doppler index of combined systolic and
diastolic function, was calculated as isovolumic relaxation time
plus isovolumic contraction time divided by ejection time.28
All patients underwent repeat assessment at 3 and 6 months of
follow up.
2.1. Statistical analysis
Continuous variables are expressed as mean  standard devia-
tion (SD), and categorical variables as percent. Student’s t test and chi-
square analysis were carried out for comparison of continuous and
categorical variables, respectively and p value 0.05 was considered
signiﬁcant. Paired t-test was carried out for comparison of variables
before and after RT. All statistical analysis was done using IBM SPSS
Statistical Software (IBM SPSS Statistics version 15.0, IBM SPSS, USA).
3. Results
A total of 100 patients (mean age 47.7  7 years, 77% males) with
a mean NYHA class (2.17  0.5) were included in the study. The mean
LVEF was (27.3  5.3, range of EF 11.8  38.18.) while mean BNP
level was 681.5  733.7 pg/ml (range 5–4240) Overall, 26% had
hypertension while 20% had diabetes. All patients were receiving
ACEI and BB, while 80 and 84% were receiving diuretics and digoxin
respectively. The mean dose of ACEI was 9.2  4.7 mg, BB
8.25  4.5 mg and diuretics was 38.0  12.5 mg respectively
(Table 1).
Fifty patients were randomized to receive TMZ in addition to
conventional therapy while 50 received conventional therapy
alone. The two groups were comparable in age, body mass index,
gender distribution, prevalence of hypertension or diabetes, NYHA
functional class, 6 min walk time, BNP levels, LVD-36 score and
hemodynamic parameters (Table 1).
There was no signiﬁcant difference in the two groups in terms of
baseline LVES and LVED dimensions, indexed volumes and EF
(Table 2). Baseline FS (20.9  4.3 vs 20.7  3.4, p = 0.25), SV
(50.2  12.3 vs 49.9  13.3 ml, p = 0.89), SVRI (15.3  4.4 vs
14.4  5.4, p = 0.26) and LV wall stress (93.2  18.9 vs 87.3 
17.9 mmHg, p = 0.22) were also comparable. Baseline diastolic and
tissue Doppler echocardiographic parameters were also comparable
amongst the two groups.
The drug was well tolerated and none of the patients
discontinued the drug due to adverse effects, and the dose did
not require to be modiﬁed during the study. There was no
signiﬁcant change in any biochemical parameters during follow up
including renal function, blood sugar or lipid levels.
Table 1
Baseline demographics of patients.
Parameter Total patients (100) TMZ (50) Control (50) p value
Age (years) 47.7  12.0 47.1  12.6 48.31  11.5 0.629
BMI 24.0  4.13 24.6  4.5 23.3  3.5 0.098
Male:female (%) 74:26 73:27 75:25 0.143
Hypertension 26% 29% 21% 0.258
Diabetes 20% 19.2% 20.8% 0.179
Duration of symptoms (months) 14.84  10.36 13.3  8.4 16.5  11.9 0.12
NYHA class 2.17  0.5 2.25  0.5 2.08  0.4 0.092
Heart rate 82.3  8.5 81.9  9.0 88.2  7.9 0.293
Systolic BP 124.8  22.6 126.8  20.9 122.1  12.3 0.07
Diastolic BP 80.4  14.5 81.73  15.5 79.4  8.3 0.358
6 min walk test (m) 347.76  83.83 349.8  89.6 345.6  77.9 0.804
BNP (pg/ml) 741.46  733.7 744.7  834.9 712.9  606.8 0.372
LVD-36 score 24.99  4.6 25.5  4.9 24.4  4.1 0.233
% on diuretics 80 79 81
% on digoxin 84 83 85
Table 2
Baseline systolic echocardiographic parameters (TMZ vs control).
Parameter TMZ (52) Control (48) p value
LVESD (mm) 4.97 + 0.69 4.98 + 0.62 0.91
LVEDD (mm) 6.2 + 0.6 6.2 + 0.7 0.90
LVESVI (ml/m2) 87.1 + 27.5 81.9 + 21.7 0.30
LVEDVI (ml/m2) 117.6 + 29.3 112.9 + 27.8 0.82
LVEF (%) 27.0  6.2 27.6  4.2 0.58
E/A velocity 1.94  1.12 2.08  1.20 0.53
E VTI/A VTI 2.69  1.99 2.77  1.78 0.8
MPI 0.80  0.17 0.75  0.11 0.07
E vel/TDIe0 septal 19.74  9.93 17.95  8.58 0.34
E vel/TDIe0 lateral 13.35  5.17 12.38  5.04 0.34
LVESD, left ventricular end-systolic dimension; LVEDD, left ventricular end-
diastolic dimension; LVESVI, left ventricular end-systolic volume indexed to body
surface area; LVEDVI, left ventricular end-diastolic volume indexed to body surface
area; LVEF, left ventricular ejection fraction; MPI, myocardial performance index.
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There was a signiﬁcant improvement in mean NYHA Class
(2.25  0.5 to 1.85  0.46, p = 0.001), 6 min walk distance (349.8 
89.6 to 402.1  87.6, p = 0.001), LVD-36 score (25.5  4.99 to
21.03  4.6, p = 0.001) along with reduction in mean BNP levels
(744.7  834.9 to 248.3  278.5, p = 0.001) after 3 months of TMZ use.
There was no signiﬁcant change in heart rate, systolic or diastolic BP
in patients receiving TMZ.
Amongst those on conventional therapy alone, there was no
signiﬁcant change in mean NYHA class (2.08  0.4 to 2.02  0.32,
p = 0.322), 6 min walk test (345.6  77.9 to 348.96  63.6, p = 0.53)
and LVD-36 score (24.4  4.1 to 24.14  3.14, p = 0.225), while
BNP levels demonstrated a signiﬁcant fall (712.9  606.8 to
455.44  475.87, p = 0.001). However BNP levels at 3 months in thisTable 3
Comparison of echo parameters at baseline, 3 and 6 months in TMZ group.
Parameter Baseline (52) 3-Month (52) 
LVESD (mm) 4.97 + 0.69 4.78  0.69 
LVEDD (mm) 6.2 + 0.6 6.20  0.65 
LVESVI (ml/m2) 87.1 + 27.5 78.5  24.9 
LVEDVI (ml/m2) 117.6 + 29.3 110.9  27.4 
LVEF (%) 27.0  6.2 30.9  6.51 
E/A velocity 1.94  1.12 1.19  0.6 
E VTI/A VTI 2.7  1.9 1.6  0.7 
MPI 0.80  0.2 0.72  0.10 
E vel/TDIe0 septal 19.7  9.9 12.5  5.8 
E vel/TDIe0 lateral 13.3  5.2 9.4  3.7 
All abbreviations as in Table 2.
The ﬁrst p value represents comparison between baseline and 3 months.
The second p value (*) represents comparison between 3 and 6 months.group were still signiﬁcantly higher than those receiving TMZ
(455.44 vs 248.3 pg/ml, p +0.009).
Patients receiving TMZ demonstrated signiﬁcant reduction in
LVES and LVED dimensions and volumes along with improvement
in EF (27.0  6.2 to 30.9  6.51, p = 0.001) (Table 3). Parameters like
SV (50.2  12.3 vs 53.3  13.5 ml, p = 0.001), FS (20.9  4.3 to
23.14  4.11, p = 0.0001), SVR (15.3  4.4 to 14.42  4.73 p = 0.05)
and LV wall stress (93.2  18.9 vs 71.1  13.2 mmHg, p = 0.0001) also
improved signiﬁcantly.
The mean transmitral E/A velocity ratio, E/A VTI, MPI, TDI E/E0
(septal) and TDI E/E0 (lateral) all improved signiﬁcantly in the TMZ
group (Table 3). The % improvement in MPI, TDI E/E0 (septal) and
TDI E/E0 (lateral) was 10%, 36% and 29.2% respectively.
In the control group, there was no signiﬁcant change in LV
dimensions and volumes. LVEF (27.6  4.2 to 27.80  4.78,
p = 0.42), SV (49.9  13.3 to 50.4  13.4 ml, p = 0.08), FS (20.7 
3.4 to 20.83  3.49, p = 0.66) and SVR (14.4  5.4 to 14.89  5.43,
p = 0.41) also did not demonstrate any signiﬁcant change at 3 months.
Only LV wall stress exhibited a reduction (87.3  17.9 to
76.47  17.43 mmHg, p = 0.03) albeit to a lesser extent than in the
TMZ group. None of the parameters of diastolic function including
transmitral E/A velocity ratio, E/A VTI or tissue Doppler parameters
(TDI E/E0 (septal) and TDI E/E0 (lateral) or MPI showed any signiﬁcant
change in those not receiving TMZ, Table 4).
3.2. Six month follow up
Patients on TMZ had further improvement in NYHA Class (from
1.85  0.46 to 1.28  0.49, p = 0.001) and LVD-36 score
(21.03  4.6 to 16.14  5.15, p = 0.001). The 6 min walk test and
BNP levels also showed a sustained improvement at 6 months (Fig. 1a
and b).p value 6-Month (50) p value*
0.0001 4.51  0.71 0.001
0.0001 6.00  0.65 0.001
0.0001 68.48  23.11 0.001
0.0001 103.02  25.22 0.001
0.0001 34.84  8.10 0.001
0.001 1.01  0.43 0.001
0.001 1.38  0.54 0.001
0.001 0.64  0.08 0.001
0.001 10.26  5.10 0.001
0.001 8.03  3.06 0.001
Table 4
Comparison of echo parameters at baseline, 3 and 6 months in control group.
Parameter Baseline 3-Month p value 6-Month p value*
LVESD (mm) 4.98 + 0.62 5.00  0.06 0.184 5.03  0.62 0.53
LVEDD (mm) 6.28 + 0.68 6.31  0.65 0.017 6.36  0.66 0.113
LVESVI (ml/m2) 81.9 + 21.7 82.31  21.54 0.532 84.21  24.31 0.210
LVEDVI (ml/m2) 112.9 + 27.8 113.65  27.41 0.228 115.73  29.74 0.173
LVEF (%) 27.6  4.2 27.80  4.78 0.42 27.69  5.56 0.893
E/A velocity 2.08  1.20 1.94  0.97 0.48 1.91  0.93 0.830
E VTI/A VTI 2.77  1.78 3.12  5.28 0.640 3.28  5.93 0.940
MPI 0.75  0.11 0.73  0.14 0.948 0.74  0.25 0.863
E vel/TDIe0 septal 17.95  8.58 17.13  7.19 0.108 17.34  6.87 0.631
E vel/TDIe0 lateral 12.38  5.04 12.04  4.32 0.329 12.42  3.99 0.826
All abbreviations as in Table 3.
The ﬁrst p value represents comparison between baseline and 3 months.
The second p value (*) represents comparison between 3 and 6 months.
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slightly (2.02  0.32 to 1.85  0.5, p = 0.04) there was a non-signiﬁcant
trend toward reduction in BNP levels (455.44  475.87 to
382.96  400.7, p = 0.07). The 6 min walk test and LVD-36 score did
not show any further improvement at 6 months (Fig. 1a and b).
Patients on TMZ had a sustained improvement in all
echocardiographic parameters at 6 months with the LVEF
improving from 30.9  6.51% at 3 months to 34.84  8.1% at
6 months, SV (53.3  13.5 to 56.8  13.6 ml, p = 0.001), FS
(23.14  4.11 to 25.18  5.01, p = 0.001) and LV wall stress
(71.1  13.2 to 56.4  14.9 mmHg, p = 0.001). Amongst those on
conventional therapy, there was no further improvement in any
echocardiographic parameter at 6 months (Tables 3 and 4).Fig. 1. (a) Change in 6 min walk test in TMZ and controls. (b) Change in BNP levels in
TMZ and controls.3.3. Changes in use of CV drugs
At 3 months amongst those receiving TMZ, rates of usage of
diuretics and digoxin was 61.5 and 63.5% respectively, while in those
on conventional therapy, the corresponding rate was 73% (p = ns for
diuretics) and 79.2% (p = 0.05 for digoxin). Those on TMZ also
required signiﬁcantly lesser doses of bb (5.9  1.4 vs 10.8  5.3 mg,
p = 0.0001) and diuretics (32.21  11.4 vs 44.27  10.6 mg, p = 0.0001).
There were two deaths in both study groups while 5 patients
required hospitalization (1 in the TMZ group and 4 in the control
group).
4. Discussion
The results of the present study indicate that trimetazidine, a
partial inhibitor of FFA oxidation, when added to conventional
therapy in patients with DCM and HF, improved NYHA functional
class, 6 min walk test, quality of life and diverse parameters of LV
systolic and diastolic function within 3 months of initiation of
therapy. In those receiving conventional therapy alone, there was
no signiﬁcant change in mean NYHA class, 6 min walk test, LVD-36
score and echocardiographic parameters.
Amongst those taking TMZ, the mean NYHA functional class
improved by 1–2 grades in 37% while none of these patients had
any deterioration in NYHA class. In contrast, in those receiving
conventional therapy, NYHA class deteriorated by grade 1–2 in
11.5%, improved in 7.5% and remained stable in 80%. By 3 months
of follow up, patients on TMZ had a signiﬁcant reduction in LVES
and LVED dimensions and volumes and LV wall stress along with
improvement in FS. The % change in LVESV, LVEDV, FS and LV wall
stress was 9.5%, 5.4%, +8.4% and 21.8% respectively. A greater
absolute % fall in LVES volume (9.5%) as compared to LVED
volume (5.4%) resulted in a signiﬁcant improvement in LVEF
(+9.4%). This improvement in LVEF is in keeping with what has
been reported previously in patients with both ischemic and non-
ischemic HF (9%,17 7%,22 18%,23 15%,24 14%29).
Patients receiving TMZ had further improvement in NYHA Class,
LVD-36 score, 6 min walk test and BNP levels at 6 months. This group
also had a sustained improvement in all echocardiographic
parameters at 6 months (change in LVESVI of 12.4%, LVEDVI of
7.8%, EF +10.9%, LV wall stress of 18.3% and MPI 9.6%). Amongst
those on conventional therapy, there was no further improvement in
any echocardiographic parameter at 6 months.
Since therapeutic interventions which potentiate shift of
myocardial substrate utilization toward glucose metabolism are
expected to protect the ischemic myocardium, the effects of TMZ
have previously been assessed mainly in patients with ischemic
HF.17–21,29 Reported beneﬁts include positive outcomes on
symptom status, exercise parameters and LV systolic function.
Although a few studies have assessed the role of TMZ role in
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included patients with both ischemic and non-ischemic HF. In
55 HF patients (ischemic n = 35, non-ischemic n = 30). Fragasso
et al. reported that while quality of life and LVD-36 improved only
in ischemic patients, TMZ signiﬁcantly improved EF regardless of
the etiology of HF, with a trend toward improvement in exercise
parameters as well.22 Use of TMZ in 12 HF patients (6 non-
ischemic) improved NYHA class, LVEF and PCr/ATP ratio which is
an indirect measure of myocardial energy utilization indicating
preservation of the myocardial high-energy phosphate levels.23
Since TMZ is only a partial and not total inhibitor of FFA oxidation,
the metabolic switch from FFA to glucose oxidation is not
complete, and hence this may not be the predominant mechanism
of action of TMZ. In support of this, in a small study of 19 patients
with DCM, Tuunanen et al. reported that although TMZ signiﬁ-
cantly improved EF in non-ischemic HF, myocardial FFA oxidation
was only modestly decreased; TMZ was postulated to have other
extra-cardiac metabolic effects like enhanced insulin sensitivity
and resultant increased glucose oxidation.24 Other studies have
also reported improved whole-body insulin sensitivity and glucose
control with TMZ in insulin-resistant idiopathic DCM as well as
diabetic patients with ischemic HF.19,30
Diastolic function: An important ﬁnding of the present study is
the improvement in parameters of diastolic function as well, after
3–6 months of TMZ. Chronic LV dysfunction alters diastolic
function and can progressively impair ventricular compliance,
further aggravating LV ﬁlling and forward ﬂow. Data on
amelioration of diastolic function in chronic HF after TMZ therapy
are limited.20,31 No other study has previously reported beneﬁt
with TMZ on diverse parameters like E/A ratio, E/A VTI, global
myocardial performance index (MPI) as well as tissue Doppler
parameters (E/E0 septal and E/E0 lateral) in chronic HF secondary to
DCM.
Biomarker and exercise tolerance: Clinical and echocardiographic
improvement in our patients on TMZ was accompanied by a
signiﬁcant fall in BNP from 744.7  834.9 to 248.3  278.5 pg/ml,
reﬂecting a % reduction of 56.8% at 3 months. Although patients on
conventional therapy also exhibited a fall in BNP (712.9  606.8 to
455.44  475.87 pg/ml, fall of 25.6%), the quantum of change was
lesser and BNP levels at follow up were higher than in patients on
TMZ. Improvement in plasma markers of HF severity with TMZ has
been reported previously and reﬂects the favorable effect of the drug
on neurohormonal pathways in chronic HF and amelioration of LV
remodeling.22,32
Although we observed a signiﬁcant improvement in the 6 min
walk test at 3 months, previous studies assessing changes in
functional capacity have reported conﬂicting results. While
Fragasso et al.23 failed to demonstrate signiﬁcant improvement
in total exercise duration with TMZ, others have reported increased
peak METS, improvement in peak exercise VO2 and better exercise
tolerance in patients with HF treated with TMZ.18,22,32 These
contrasting results reﬂect differences in patient populations and
types of exercise protocols use in the various studies.
Since all patients in our study were receiving bb and ACEI, the
improvement in functional status, 6 min walk test and all
echocardiographic variables in the TMZ group, indicates that
TMZ can improve cardiac function even when added on the
background of current standard therapies. It has been reported that
a greater beneﬁt of TMZ was evident in patients of HF with a higher
degree of b-blockade (as estimated by a b1-adrenoceptor
occupancy), suggesting an additive effect of TMZ and bb in
patients with HF and DCM.24
Drug tolerance and change in medications: The drug was well
tolerated and none of the patients required discontinuation of the
study medication. Absence of systemic hemodynamic effects with
no signiﬁcant change in systolic or diastolic BP or heart rate, werein keeping with the known pharmacological actions of TMZ.10,11
Use of TMZ resulted in signiﬁcantly lesser use of digoxin (63.5% vs
79.2%, p = 0.04) and a trend toward lesser use of diuretics (61.5% vs
72.9%) at 3 months; the mean dose of bb and diuretics was also
signiﬁcantly lesser in those randomized to receive TMZ.
Mortality beneﬁt: Given the improvement in LVEF with TMZ, it is
important to know if these beneﬁts translate into improved
prognosis and survival. In a meta-analysis of randomized trials of
TMZ in HF, Zhang et al. concluded that although there was no
mortality beneﬁt, improvement in symptoms, LVEF and hospitali-
zation rates for cardiac causes was demonstarble.33 In contrast,
Gao et al. in their meta-analysis reported that TMZ therapy was
associated with improved all-cause mortality and reduction in
cardiovascular events and hospitalizations.34 Reduction in mortal-
ity and better event-free survival in patients with CHF with TMZ
has also been reported in a recent international multicentre
retrospective cohort study.35
We did not ﬁnd any signiﬁcant differences in death (1 in each
group). Overall 4 patients required hospitalization for recurrent HF
in the conventional therapy group as compared to only 1 in the
TMZ group. The low event rate along with a follow up of only 3–6
months in our study precluded us from making any meaningful
conclusions on the effect of TMZ in improving survival or reducing
mortality.
5. Limitations
Our study included 100 patients (50 in each group) and the
small sample size represents an important limitation. More studies
need to be performed with larger patient numbers to further clarify
the role of TMZ in HF secondary to DCM. The effects of TMZ were
observed at 3–6 months of follow up. Longer follow up with a
larger sample size will also help determine the effect of TMZ of
reduction of all cause/cardiac mortality in patients with non-
ischemic HF.
6. Conclusion
Trimetazidine, a speciﬁc partial inhibitor of FFA oxidation,
added to usual treatment improved NYHA functional class,
exercise tolerance, quality of life, and various echocardiographic
parameters of left ventricular function in patients with HF
secondary to non-ischemic DCM. The drug was well tolerated
and beneﬁcial effects were observed within 3 months of initiation
of therapy with sustained and consistent improvement noticed till
6 months of follow up.
What is already known?
 Myocardial dysfunction in HF is due to altered substrate
energy metabolism with reduction in mitochondrial oxida-
tive metabolism and down-regulation of glucose and free
fatty acid oxidation.
What this study adds?
 This study adds to the existing evidence that metabolic
modulation with trimetazidine (a partial inhibitor of free
fatty oxidation), improves NYHA functional class, exercise
tolerance and diverse echocardiographic parameters of left
ventricular function in patients with heart failure.
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